NCT07500155Completed
Postmarket Study of Tarvos Microguidewire in Neurovascular Interventional Surgery
Evaluation of Clinical Effectiveness and Safety of Tarvos Microguidewire in Neurovascular Interventional Surgery
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
This investigation is to evaluate the clinical effectiveness and safety of the Tarvos Microguidewire in the neurovascular interventional surgery. It is a retrospective multicenter medical device clinical study with real-world data.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 121 (actual)
- First submitted
- 24 Mar 2026
- Start date
- 29 Jan 2026
- Primary completion date
- 15 Mar 2026
- Lead sponsor
- Keuro MedTech
- Diseases
- Stroke
- NCT number
- NCT07500155
What you commit to
- Study type: Observational
- Participants enrolled: 121
- From 29 Jan 2026 to the primary completion date, 15 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior vascular dissection or injury to the target vessels
Other illness
- Disorders of vascular fragility (e.g. Ehlers-Danlos syndrome)
Other
- Not meeting the data requirements needed for this study.
Who the study is looking for
- Undertaken a neurovascular surgery procedure including Tarvos microguidewire
- Available images of Tarvos Microguidewire in the neurovascular surgery.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xingtai central hospital Coordinator of this site? Confirm its status | Xingtai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.